- Home
- AVIR vs ABEO Comparison
AVIR vs ABEO Comparison
Compare AVIR & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | ABEO |
|---|---|---|
| Founded | 2012 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.7M | 281.0M |
| IPO Year | 2020 | 1980 |
Fundamental Metrics
Financial Performance| Metric | AVIR | ABEO |
|---|---|---|
| Price | $3.56 | $5.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $18.20 |
| AVG Volume (30 Days) | 375.3K | ★ 1.1M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | N/A | ★ $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,589.77 |
| P/E Ratio | ★ N/A | $4.10 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $3.93 |
| 52 Week High | $4.02 | $7.54 |
Technical Indicators
Market Signals| Indicator | AVIR | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 64.57 | 54.91 |
| Support Level | $3.11 | $4.80 |
| Resistance Level | $3.72 | $5.55 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 74.80 | 66.03 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.